Bristol-Myers Squibb Financial Statements
NYSE: BMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bristol-Myers Squibb revenue and earnings
In fiscal 2025, Bristol-Myers Squibb generated $48.19 billion in revenue, down 0.2% from fiscal 2024, its first annual decline since 2023. Net income was $7.05 billion, for a net margin of 14.6% versus a median of 13.7% in the prior 5 years. Gross margin was 71.1% (flat year over year).
Diluted earnings per share came in at $3.46. Over the last 5 fiscal years, BMY's revenue has grown at a 2.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Bristol-Myers Squibb income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.19B | 48.30B | 45.01B | 46.16B | 46.38B | 42.52B | 26.14B | 22.56B | 20.78B | 19.43B |
| Revenue growth (YoY) | -0.22% | +7.32% | -2.50% | -0.49% | +9.09% | +62.62% | +15.89% | +8.59% | +6.94% | +17.31% |
| Cost of Revenue | 13.94B | 13.97B | 10.69B | 10.14B | 9.94B | 11.77B | 8.08B | 6.47B | 6.01B | 4.97B |
| Gross Profit | 34.26B | 34.33B | 34.31B | 36.02B | 36.45B | 30.75B | 18.07B | 16.09B | 14.68B | 14.48B |
| Research & Development | 9.95B | 11.16B | 9.30B | 9.51B | 10.20B | 10.05B | 6.15B | 6.33B | 6.47B | 5.01B |
| Selling, General & Admin | 7.27B | 8.41B | 7.77B | 7.81B | 7.69B | 7.66B | 4.87B | 4.55B | 4.75B | 4.98B |
| Interest Expense | 1.89B | 1.95B | 1.17B | 1.23B | 1.33B | 1.42B | 656.00M | 183.00M | 196.00M | 167.00M |
| Other Income (Expense) | -674.00M | -893.00M | 1.16B | -576.00M | 720.00M | 2.31B | -938.00M | 854.00M | 1.69B | 1.45B |
| Pretax Income | 9.33B | -8.38B | 8.44B | 7.71B | 8.10B | -6.87B | 4.97B | 5.97B | 5.13B | 5.92B |
| Income Tax | 2.27B | 554.00M | 400.00M | 1.37B | 1.08B | 2.12B | 1.51B | 1.02B | 4.16B | 1.41B |
| Net Income | 7.05B | -8.95B | 8.03B | 6.33B | 6.99B | -9.02B | 3.44B | 4.92B | 1.01B | 4.46B |
| Net Income growth (YoY) | — | -211.50% | +26.84% | -9.54% | — | -362.14% | -30.10% | +388.58% | -77.41% | +184.79% |
| EPS (Basic) | 3.47 | -4.41 | 3.88 | 2.97 | 3.15 | -3.99 | 2.02 | 3.01 | 0.61 | 2.67 |
| EPS (Diluted) | 3.46 | -4.41 | 3.86 | 2.95 | 3.12 | -3.99 | 2.01 | 3.01 | 0.61 | 2.65 |
| Shares Outstanding (Basic) | 2.03B | 2.03B | 2.07B | 2.13B | 2.22B | 2.26B | 1.71B | 1.63B | 1.65B | 1.67B |
| Shares Outstanding (Diluted) | 2.04B | 2.03B | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B | 1.64B | 1.65B | 1.68B |
| Gross Margin | 71.08% | 71.08% | 76.24% | 78.04% | 78.57% | 72.31% | 69.10% | 71.34% | 70.67% | 74.54% |
| Net Margin | 14.64% | -18.53% | 17.83% | 13.71% | 15.08% | -21.20% | 13.15% | 21.81% | 4.85% | 22.94% |
This table shows 10 annual periods of Bristol-Myers Squibb's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BMY's reporting calendar. What is a income statement?